CAR T cells are patient-derived T lymphocytes that have been genetically modified to express chimeric antigen receptors targeting tumor-associated antigens, such as CD19 or B-cell maturation antigen (BCMA), thereby promoting tumor cell apoptosis. The gene discussed is CD19; the disease is neoplasm.